» Articles » PMID: 38439837

Bridging the Gap Between Statistical Significance and Clinical Relevance: A Systematic Review of Minimum Clinically Important Difference (MCID) Thresholds of Scales Reported in Movement Disorders Research

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Mar 5
PMID 38439837
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Minimum clinically important difference MCID) is the smallest change in an outcome measure that is considered clinically meaningful. Using validated MCID thresholds for outcomes powers trials adequately to detect meaningful treatment effects, aids in their interpretation and guides development of new outcome measures.

Objectives: To provide a comprehensive summary of MCID thresholds of various symptom severity scales reported in movement disorder.

Methods: We conducted systematic review of the literature and included studies of one or more movement disorders, and reporting MCID scales.

Results: 2763 reports were screened. Final review included 32 studies. Risk of bias (RoB) assessment showed most studies were of good quality. Most commonly evaluated scale was Unified Parkinson's Disease Rating Scale (UPDRS) (11 out of 32). Four studies assessing MDS-UPDRS had assessed its different sub-parts, reporting a change of 2.64,3.05,3.25 and 0.9 points to detect clinically meaningful improvement and 2.45,2.51,4.63 and 0.8 points to detect clinically meaningful worsening, for the Part I, II, III and IV, respectively. For Parts II + III, I + II + III and I + II + III + IV, MCID thresholds reported for clinically meaningful improvement were 5.73, 4.9, 6.7 and 7.1 points respectively; while those for clinically meaningful worsening were 4.7, 4.2, 5.2 and 6.3 points, respectively. MCID thresholds reported for other scales included Abnormal Involuntary Movement Scale (AIMS), Toronto Western Spasmodic Torticollis Rating Scale (TWSRS), and Burke-Fahn-Marsden Dystonia Scale (BFMD).

Conclusion: This review summarizes all the MCID thresholds currently reported in Movement disorders research and provides a comprehensive resource for future trials, highlighting the need for standardized and validated MCID scales in movement disorder research.

Citing Articles

L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Ishihara T, Tada M, Kanemitsu Y, Takahashi Y, Ishikawa K, Ikenaka K EClinicalMedicine. 2025; 78():102952.

PMID: 39764542 PMC: 11701440. DOI: 10.1016/j.eclinm.2024.102952.


Comparison of externally and internally guided dance movement to address mobility, cognition, and psychosocial function in people with Parkinson's disease and freezing of gait: a case series.

Abraham A, Hart A, Bozzorg A, Pothineni S, Wolf S, Schuh K Front Aging Neurosci. 2024; 16:1372894.

PMID: 38813534 PMC: 11135342. DOI: 10.3389/fnagi.2024.1372894.

References
1.
Poewe W, Seppi K, Fitzer-Attas C, Wenning G, Gilman S, Low P . Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2014; 14(2):145-52. DOI: 10.1016/S1474-4422(14)70288-1. View

2.
Mestre T, Beaulieu-Boire I, Aquino C, Phielipp N, Poon Y, Lui J . What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?. Parkinsonism Relat Disord. 2015; 21(11):1349-54. DOI: 10.1016/j.parkreldis.2015.09.044. View

3.
Rascol O, Brooks D, Brunt E, Korczyn A, Poewe W, Stocchi F . Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. 1998; 13(1):39-45. DOI: 10.1002/mds.870130111. View

4.
Hauser R, Factor S, Marder S, Knesevich M, Ramirez P, Jimenez R . KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017; 174(5):476-484. DOI: 10.1176/appi.ajp.2017.16091037. View

5.
Poewe W, Rascol O, Barone P, Hauser R, Mizuno Y, Haaksma M . Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Neurology. 2011; 77(8):759-66. DOI: 10.1212/WNL.0b013e31822affb0. View